UK markets open in 5 hours 28 minutes
  • NIKKEI 225

    28,729.57
    +182.59 (+0.64%)
     
  • HANG SENG

    20,175.62
    0.00 (0.00%)
     
  • CRUDE OIL

    91.47
    -0.62 (-0.67%)
     
  • GOLD FUTURES

    1,813.90
    -1.60 (-0.09%)
     
  • DOW

    33,761.05
    +424.35 (+1.27%)
     
  • BTC-GBP

    20,120.03
    -203.91 (-1.00%)
     
  • CMC Crypto 200

    582.85
    +11.56 (+2.02%)
     
  • ^IXIC

    13,047.19
    +267.29 (+2.09%)
     
  • ^FTAS

    4,149.90
    +18.64 (+0.45%)
     

MaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 years

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MaxCyte, Inc. (LON:MXCT) shareholders might be concerned after seeing the share price drop 28% in the last quarter. But in three years the returns have been great. The share price marched upwards over that time, and is now 112% higher than it was. So the recent fall in the share price should be viewed in that context. Only time will tell if there is still too much optimism currently reflected in the share price.

Although MaxCyte has shed US$98m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

View our latest analysis for MaxCyte

MaxCyte wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

MaxCyte's revenue trended up 25% each year over three years. That's well above most pre-profit companies. Along the way, the share price gained 28% per year, a solid pop by our standards. But it does seem like the market is paying attention to strong revenue growth. Nonetheless, we'd say MaxCyte is still worth investigating - successful businesses can often keep growing for long periods.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think MaxCyte will earn in the future (free profit forecasts).

A Different Perspective

While the broader market lost about 0.5% in the twelve months, MaxCyte shareholders did even worse, losing 62%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 3% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 4 warning signs for MaxCyte (1 is concerning!) that you should be aware of before investing here.

MaxCyte is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting